Literature DB >> 21643013

Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations.

S Floor1, W C G van Staveren, D Larsimont, J E Dumont, C Maenhaut.   

Abstract

Cell populations of solid cancers and their distant models, the cancer cell lines, have been categorized in sub-populations: cancer stem-tumor-propagating cells (CSC-TPC) versus derived cells, epithelial- versus mesenchymal-type cells, dormant versus actively proliferating cells and so on. CSC-TPC are minimally defined by their operational properties: immortality and the ability to regenerate in vivo or in vitro the whole panel of cancer cells. The epithelial-to-mesenchymal transition (EMT), mostly observed in vitro, generates mesenchymal-type from epithelial-type cells. The converse transition is mesenchymal-to-epithelial transition. In vitro work suggests that CSC-TPC and EMT cell phenotypes overlap. An analysis of the properties of these sub-populations, as studied in vitro, shows that indeed these two phenotypes may be linked to some extent. However, the in vivo counterpart of this relation in human tumors has barely been investigated. A model in which among the EMT cells released from the tumor only the most competent CSC-TPC will succeed to metastasize is proposed. It is suggested that in the Darwinian evolution of cancer cells, many phenotypes reflecting the expression of various programs, reversible to irreversible, exclusive, overlapping or linked coexist and compete with each other.

Entities:  

Mesh:

Year:  2011        PMID: 21643013     DOI: 10.1038/onc.2011.184

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  85 in total

Review 1.  Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer.

Authors:  Robert Strauss; Petra Hamerlik; André Lieber; Jiri Bartek
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

2.  Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy.

Authors:  Bingxue Shang; Gaochuan Zhang; Yanyan Pan; Quansheng Zhou
Journal:  Cancer Microenviron       Date:  2012-05-17

3.  Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.

Authors:  Yang Li; Kangdong Chen; Lei Li; Rui Li; Juxin Zhang; Wu Ren
Journal:  Tumour Biol       Date:  2015-07-11

Review 4.  Tracking the intermediate stages of epithelial-mesenchymal transition in epithelial stem cells and cancer.

Authors:  Nicole Vincent Jordan; Gary L Johnson; Amy N Abell
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

5.  Epithelial-mesenchymal transition enhances response to oncolytic herpesviral therapy through nectin-1.

Authors:  Chun-Hao Chen; Wei-Yi Chen; Shu-Fu Lin; Richard J Wong
Journal:  Hum Gene Ther       Date:  2014-04-02       Impact factor: 5.695

6.  Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts.

Authors:  Doudou Li; Chao Qu; Zhouyu Ning; Haiyong Wang; Kun Zang; Liping Zhuang; Lianyu Chen; Peng Wang; Zhiqiang Meng
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

7.  Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens.

Authors:  Darue A Prieto; Donald J Johann; Bih-Rong Wei; Xiaoying Ye; King C Chan; Dwight V Nissley; R Mark Simpson; Deborah E Citrin; Crystal L Mackall; W Marston Linehan; Josip Blonder
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

8.  MicroRNA-26a regulates ANXA1, rather than DAL-1, in the development of lung cancer.

Authors:  Tonghui Cai; Xiaoying Guan; Hongyan Wang; Ying Fang; Jie Long; Xiaobin Xie; Yajie Zhang
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

9.  Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Authors:  Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-09-17       Impact factor: 4.534

10.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.